Elite Journal of Haematology. Volume 2 issue 2(2024), Pp. 70-79

https://epjournals.com/journals/EJH

Hematological Horizons: Diabetes Care Considerations in Sickle Cell Anemia - A Review

*Emmanuel Ifeanyi Obeagu[1] and Getrude Uzoma Obeagu[2]

[1]Department of Medical Laboratory Science, Kampala International University, Ishaka, Uganda.
[2]School of Nursing Science, Kampala International University, Ishaka, Uganda.

*Corresponding authour: Emmanuel Ifeanyi Obeagu, Department of Medical Laboratory Science, Kampala International University, Uganda.

E-mail: emmanuelobeagu@yahoo.com, obeagu.emmanuel@kiu.ac.ug, 0000-0002-4538-0161

Abstract

This review delves into the intricate relationship between sickle cell anemia and diabetes, shedding light on the unique challenges and considerations in diabetes care for individuals affected by this hemoglobinopathy. Sickle cell anemia, a hereditary blood disorder characterized by abnormal hemoglobin, introduces complexities in managing diabetes that extend beyond those encountered in the general population. Chronic inflammation, oxidative stress, and an increased risk of vaso-occlusive crises associated with sickle cell anemia can impact insulin resistance and glycemic control. Through an examination of existing literature, this review synthesizes available knowledge, addresses research gaps, and proposes tailored care strategies. Emphasizing the need for a comprehensive and personalized approach to diabetes care in this unique patient demographic, the review aims to contribute to the advancement of evidence-based practices and improve clinical management for individuals navigating the complex intersection of sickle cell anemia and diabetes.

Keywords*: Sickle Cell Anemia, Diabetes, Hematological Disorders, Co-morbidities, Tailored Care Strategies*

Introduction

Sickle cell anemia, a hereditary blood disorder characterized by the presence of abnormal hemoglobin, stands as a complex and multifaceted challenge within the realm of hematological disorders.[1-3] This condition, prevalent in various populations worldwide, particularly those of African, Mediterranean, and Middle Eastern descent, manifests unique clinical features that extend beyond its primary impact on red blood cells. One significant aspect of this complexity arises from

the intersection of sickle cell anemia with diabetes, presenting a novel confluence of challenges for healthcare providers and researchers alike. As individuals with sickle cell anemia pass through the intricacies of their hematological disorder, the coexistence of diabetes introduces an added layer of complexity to their healthcare landscape. Diabetes, a metabolic disorder characterized by impaired insulin function and elevated blood glucose levels, poses specific challenges in the context of sickle cell anemia. The chronic inflammation and oxidative stress associated with sickle cell anemia may exacerbate insulin resistance, potentially influencing the course of diabetes in affected individuals. Moreover, the proclivity for vaso-occlusive crises and organ damage in sickle cell patients adds further dimensions to the already intricate tapestry of managing diabetes within this unique patient demographic.[4-24]

Understanding the interplay between sickle cell anemia and diabetes necessitates a comprehensive exploration of existing literature, research findings, and clinical observations. The scarcity of literature on this specific intersection underscores the need for a thorough review to consolidate available knowledge, identify research gaps, and propose avenues for further investigation. Through this review, we aim to provide a synthesized understanding of the challenges posed by the coexistence of sickle cell anemia and diabetes, thereby contributing to the development of evidence-based practices and tailored care strategies. This review is not merely an exploration of the challenges; it is a call to action for the medical and research communities to delve deeper into the intricacies of this unique intersection. By recognizing the gaps in our current understanding and proposing strategies for improved diabetes care within the context of sickle cell anemia, we hope to enhance the quality of life for individuals grappling with these intertwined health challenges. Through a multidisciplinary approach and a focus on precision medicine, this review aims to offer insights that can guide healthcare practitioners, researchers, and policymakers toward more effective interventions and holistic care strategies for those navigating the complex landscape of sickle cell anemia and diabetes co-occurrence.[25-44]

Challenges in Diabetes Care for Sickle Cell Anemia

The challenges in diabetes care for individuals with sickle cell anemia are multifaceted, stemming from the intricate interplay between the pathophysiological mechanisms of both conditions. Sickle cell anemia, a hereditary hemoglobinopathy, is characterized by the presence of abnormal hemoglobin, leading to the distortion of red blood cells and causing vaso-occlusive events. These events can obstruct blood flow, exacerbate ischemia, and create a pro-inflammatory milieu within the vascular system. The chronic inflammatory state associated with sickle cell anemia poses a unique challenge in managing diabetes, as inflammation is known to contribute to insulin resistance and impair glucose homeostasis. Moreover, individuals with sickle cell anemia are often at an increased risk of experiencing vaso-occlusive crises, during which blood vessels become obstructed by sickled red blood cells. These crises can lead to organ damage and compromise blood supply, further complicating the management of diabetes. The recurrent nature of vaso-

occlusive events not only hinders glycemic control but also necessitates a careful balance between addressing acute crises and implementing long-term diabetes management strategies.[45-64]

In addition to the physiological challenges, the socioeconomic factors that disproportionately affect individuals with sickle cell anemia also impact diabetes care. Limited access to healthcare resources, financial constraints, and a lack of awareness about the intricate relationship between sickle cell anemia and diabetes contribute to disparities in healthcare delivery. The scarcity of research focusing on this specific comorbidity adds another layer of complexity, leaving healthcare providers with limited evidence-based guidelines for managing diabetes in individuals with sickle cell anemia. The coexistence of diabetes and sickle cell anemia underscores the necessity for a tailored and multidisciplinary approach to care. As clinicians navigate these challenges, it becomes imperative to recognize the unique pathophysiological aspects of both conditions, understand their synergistic effects, and develop comprehensive strategies that address the complexities of diabetes management in individuals with sickle cell anemia.[65-74]

Tailored Care Strategies

Tailoring care strategies for individuals navigating the intricate intersection of sickle cell anemia and diabetes is imperative to address the unique challenges posed by these coexisting conditions. A multidisciplinary approach that integrates expertise from hematology, endocrinology, and other relevant specialties is essential to develop comprehensive and patient-centered interventions. One crucial aspect of tailored care involves optimizing glycemic control while considering the heightened risk of vaso-occlusive crises in individuals with sickle cell anemia.[75] Careful monitoring of blood glucose levels, personalized insulin regimens, and anticipatory adjustments during acute sickle cell crises are paramount to prevent complications and maintain stable glycemic control. Given the chronic inflammatory state associated with sickle cell anemia, anti-inflammatory strategies may be explored to mitigate insulin resistance and enhance overall metabolic health. This may include the judicious use of anti-inflammatory medications, although further research is needed to establish their safety and efficacy in this specific population.

Educating individuals with sickle cell anemia and diabetes about the intricacies of their conditions is crucial for empowering them to actively participate in their care. Providing information about lifestyle modifications, dietary considerations, and the importance of regular medical check-ups can contribute to better self-management and improved health outcomes. Furthermore, healthcare providers should prioritize preventive measures to reduce the risk of diabetes-related complications, considering the increased susceptibility to organ damage in individuals with sickle cell anemia. Regular screenings for diabetes-related complications, such as retinopathy, nephropathy, and peripheral neuropathy, can facilitate early intervention and prevent the progression of these complications. Collaboration between healthcare providers and researchers is instrumental in developing evidence-based guidelines for managing diabetes in individuals with sickle cell anemia. Clinical trials evaluating the safety and efficacy of existing diabetes treatments

in this specific population, as well as exploring novel therapeutic approaches, can contribute to the establishment of tailored and effective care protocols.

Conclusion

The intersection of sickle cell anemia and diabetes presents a challenging landscape that demands tailored care strategies to address the distinctive complexities of these coexisting conditions. The challenges span physiological, psychosocial, and healthcare delivery domains, emphasizing the need for a comprehensive and multidisciplinary approach to patient care. Tailored care strategies must encompass vigilant glycemic control, considering the heightened risk of vaso-occlusive crises, and anti-inflammatory measures to address the chronic inflammatory state associated with sickle cell anemia. Patient education plays a pivotal role in empowering individuals to actively participate in their care, emphasizing lifestyle modifications, dietary considerations, and the importance of regular medical monitoring.

References

1. Pecker LH, Little J. Clinical manifestations of sickle cell disease across the lifespan. Sickle cell disease and hematopoietic stem cell transplantation. 2018:3-9.
2. Alapan Y, Fraiwan A, Kucukal E, Hasan MN, Ung R, Kim M, Odame I, Little JA, Gurkan UA. Emerging point-of-care technologies for sickle cell disease screening and monitoring. Expert review of medical devices. 2016;13(12):1073-1093.
3. Kuriri FA. Hope on the Horizon: New and Future Therapies for Sickle Cell Disease. Journal of Clinical Medicine. 2023;12(17):5692.
4. Obeagu EI, Obeagu GU. Implications of climatic change on sickle cell anemia: A review. Medicine. 2024;103(6):e37127.
5. Obeagu EI. Maximizing longevity: erythropoietin's impact on sickle cell anemia survival rates. Annals of Medicine and Surgery. 2024:10-97.
6. Obeagu EI, Ubosi NI, Obeagu GU, Egba SI, Bluth MH. Understanding apoptosis in sickle cell anemia patients: Mechanisms and implications. Medicine. 2024 Jan 12;103(2):e36898.
7. Obeagu EI, Obeagu GU. Dual Management: Diabetes and Sickle Cell Anemia in Patient Care. Elite Journal of Medicine. 2024;2(1):47-56.
8. Obeagu EI, Obeagu GU, Hauwa BA. Optimizing Maternal Health: Addressing Hemolysis in Pregnant Women with Sickle Cell Anemia. Journal home page: http://www. journalijiar. com.;12(01).
9. Obeagu EI, Obeagu GU. Improving Outcomes: Integrated Strategies for Diabetes and Sickle Cell Anemia. Int. J. Curr. Res. Chem. Pharm. Sci. 2024;11(2):20-9.
10. Ifediora AC, Obeagu EI, Akahara IC, Eguzouwa UP. Prevalence of urinary tract infection in diabetic patients attending Umuahia health care facilities. J Bio Innov. 2016;5(1):68-82. links/5ae45fdfaca272ba507eb3c3/PREVALENCE-OF-URINARY-TRACT-INFECTION-IN-DIABETIC-PATIENTS-ATTENDING-UMUAHIA-HEALTH-CARE-FACILITIES.pdf.

Citation: Obeagu EI, Obeagu GU. Hematological Horizons: Diabetes Care Considerations in Sickle Cell Anemia - A Review. *Elite Journal of Haematology, 2024; 2(2):* 70-79

11. Ugwu OP, Alum EU, Okon MB, Aja PM, Obeagu EI, Onyeneke EC. Ethanol root extract and fractions of Sphenocentrum jollyanum abrogate hyperglycaemia and low body weight in streptozotocin-induced diabetic Wistar albino rats. RPS Pharmacy and Pharmacology Reports. 2023;2(2):rqad010.
12. Obeagu EI, Obeagu GU. Utilization of Antioxidants in the management of diabetes mellitus patients. J Diabetes Clin Prac. 2018;1(102):2. links/5b6c2dec92851ca65053b74e/Utilization-of-Antioxidants-in-the-Management-of-Diabetes-Mellitus.pdf.
13. Obeagu EI, Okoroiwu IL, Obeagu GU. Some haematological variables in insulin dependent diabetes mellitus patients in Imo state Nigeria. Int. J. Curr. Res. Chem. Pharm. Sci. 2016;3(4):110-7. links/5ae4abee458515760ac07a13/Some-haematological-variables-in-insulin-dependent-diabetes-mellitus-patients-in-Imo-state-Nigeria.pdf.
14. Nwakuilite A, Nwanjo HU, Nwosu DC, Obeagu EI. Evaluation of some trace elements in streptozocin induced diabetic rats treated with Moringa oleifera leaf powder. WJPMR. 2020;6(12):15-8. links/5fcb587092851c00f8516430/EVALUATION-OF-SOME-TRACE-ELEMENTS-IN-STREPTOZOCIN-INDUCED-DIABETIC-RATS-TREATED-WITH-MORINGA-OLEIFERA-LEAF-POWDER.pdf.
15. Obeagu EI, Ochei KC, Nwachukwu BN, Nchuma BO. Sickle cell anaemia: a review. Scholars Journal of Applied Medical Sciences. 2015;3(6B):224422-52.
16. Obeagu EI. Erythropoeitin in Sickle Cell Anaemia: A Review. International Journal of Research Studies in Medical and Health Sciences. 2020;5(2):22-28.
17. Obeagu EI. Sickle Cell Anaemia: Haemolysis and Anemia. Int. J. Curr. Res. Chem. Pharm. Sci. 2018;5(10):20-21.
18. Obeagu EI, Muhimbura E, Kagenderezo BP, Uwakwe OS, Nakyeyune S, Obeagu GU. An Update on Interferon Gamma and C Reactive Proteins in Sickle Cell Anaemia Crisis. J Biomed Sci. 2022;11(10):84.
19. Obeagu EI, Bunu UO, Obeagu GU, Habimana JB. Antioxidants in the management of sickle cell anaemia: an area to be exploited for the wellbeing of the patients. International Research in Medical and Health Sciences. 2023 Sep 11;6(4):12-17.
20. Obeagu EI, Ogunnaya FU, Obeagu GU, Ndidi AC. Sickle cell anaemia: a gestational enigma. European Journal of Biomedical and Pharmaceutical Sciences. 2023;10((9): 72-75
21. Obeagu EI. An update on micro RNA in sickle cell disease. Int J Adv Res Biol Sci. 2018;5:157-8.
22. Obeagu EI, Babar Q. Covid-19 and Sickle Cell Anemia: Susceptibility and Severity. J. Clinical and Laboratory Research. 2021;3(5):2768-0487.
23. Obeagu EI, Obeagu GU, Igwe MC, Alum EU, Ugwu OP. Men's Essential roles in the Management of Sickle Cell Anemia. **NEWPORT INTERNATIONAL JOURNAL OF SCIENTIFIC AND EXPERIMENTAL SCIENCES 4(2):20-29**. https://doi.org/10.59298/NIJSES/2023/10.3.1111

24. Obeagu EI. Depression in Sickle Cell Anemia: An Overlooked Battle. Int. J. Curr. Res. Chem. Pharm. Sci. 2023;10(10):41-.
25. Anyiam AF, Obeagu EI, Obi E, Omosigho PO, Irondi EA, Arinze-Anyiam OC, Asiyah MK. ABO blood groups and gestational diabetes among pregnant women attending University of Ilorin Teaching Hospital, Kwara State, Nigeria. International Journal of Research and Reports in Hematology. 2022;5(2):113-121.
26. Okafor CJ, Yusuf SA, Mahmoud SA, Salum SS, Vargas SC, Mathew AE, Obeagu EI, Shaib HK, Iddi HA, Moh'd MS, Abdulrahman WS. Effect of Gender and Risk Factors in Complications of Type 2 Diabetic Mellitus among Patients Attending Diabetic Clinic in Mnazi Mmoja Hospital, Zanzibar. Journal of Pharmaceutical Research International. 2021;33(29B):67-78.
27. Galano ES, Yusuf SA, Ogbonnia SO, Ogundahunsi OA, Obeagu EI, Chukwuani U, Okafor CJ, Obianagha NF. Effect of Extracts of Kigelia Africana Fruit and Sorghum Bicolor Stalk on the Biochemical Parameters of Alloxan-Induced Diabetic Rats. Journal of Pharmaceutical Research International. 2021;33(25B):86-97.
28. Kama SC, Obeagu EI, Alo MN, Ochei KC, Ezugwu UM, Odo M, Ikpeme M, Ukeekwe CO, Amaeze AA. Incidence of Urinary Tract Infection among Diabetic Patients in Abakaliki Metropolis. Journal of Pharmaceutical Research International. 2020 Nov 17;32(28):117-121.
29. Nwakulite A, Obeagu EI, Eze R, Vincent CC, Chukwurah EF, Okafor CJ, Ibekwe AM, Adike CN, Chukwuani U, Ifionu BI. Evaluation of Catalase and Manganese in Type 2 Diabetic Patients in University of Port Harcourt Teaching Hospital. Journal of Pharmaceutical Research International. 2021:40-45.
30. Nwakulite A, Obeagu EI, Nwanjo HU, Nwosu DC, Nnatuanya IN, Vincent CC, Amaechi CO, Ochiabu O, Barbara MT, Ibekwe AM, Okafor CJ. Studies on Pancreatic Gene Expression in Diabetic Rats Treated with Moringa oleifera Leaf. Journal of Pharmaceutical Research International. 2021;33(28A):78-86.
31. Nwosu DC, Nwanjo HU, Obeagu EI, Ugwu GU, Ofor IB, Okeke A, Ochei KC, Kanu SN, Okpara KE. Evaluation of Lipoprotein A and Lipid Tetrad Index Pattern in Diabetic Patients Attending Metabolic Clinic in The Federal Medical Centre, Owerri, Imo State. World Journal of Pharmacy and Pharmaceutical Sciences, 2015; 4 (3):126-140
32. Ezema GO, Omeh NY, Egbachukwu S, Agbo EC, Ikeyi AP, Obeagu EI. Evaluation of Biochemical Parameters of Patients with Type 2 Diabetes Mellitus Based on Age and Gender in Umuahia. Asian Journal of Dental and Health Sciences. 2023 Jun 15;3(2):32-36. http://ajdhs.com/index.php/journal/article/view/43.
33. Adu ME, Chukwuani U, Ezeoru V, Okafor CJ, Amaechi CO, Vincent CC, Obeagu GU, Eze R, Nnatuanya IN, Nwosu DC, Nwanjo HU. Studies on molecular docking of moringa oleifera leaf phytochemical constituents on alpha glucosidase, alpha amylase and dipeptidyl peptidase. Journal of Pharmaceutical Research International. 2021;33(28A):239-345.

34. Ezugwu UM, Onyenekwe CC, Ukibe NR, Ahaneku JE, Obeagu EI. Plasma Level of Macromolecules and Mathematical Calculation of Potential Energy in Type 2 Diabetic Individuals at NAUTH, Nnewi, Nigeria. Journal of Pharmaceutical Research International. 2021;33(47B):242-248.
35. Obeagu EI, Obeagu GU. Evaluation of Hematological Parameters of Sickle Cell Anemia Patients with Osteomyelitis in A Tertiary Hospital in Enugu, Nigeria. Journal of Clinical and Laboratory Research.2023;6(1):2768-0487.
36. Obeagu EI, Dahir FS, Francisca U, Vandu C, Obeagu GU. Hyperthyroidism in sickle cell anaemia. Int. J. Adv. Res. Biol. Sci. 2023;10(3):81-89.
37. Obeagu EI, Obeagu GU, Akinleye CA, Igwe MC. Nosocomial infections in sickle cell anemia patients: Prevention through multi-disciplinary approach: A review. Medicine. 2023 Dec 1;102(48):e36462.
38. Njar VE, Ogunnaya FU, Obeagu EI. Knowledge And Prevalence of The Sickle Cell Trait Among Undergraduate Students Of The University Of Calabar. Prevalence.;5(100):0-5.
39. Swem CA, Ukaejiofo EO, Obeagu EI, Eluke B. Expression of micro RNA 144 in sickle cell disease. Int. J. Curr. Res. Med. Sci. 2018;4(3):26-32.
40. Obeagu EI, Nimo OM, Bunu UO, Ugwu OP, Alum EU. Anaemia in children under five years: African perspectives. Int. J. Curr. Res. Biol. Med. 2023;1:1-7.
41. Obeagu EI. Sickle cell anaemia: Historical perspective, Pathophysiology and Clinical manifestations. Int. J. Curr. Res. Chem. Pharm. Sci. 2018;5(11):13-15.
42. Obeagu EI, Obeagu GU. Sickle Cell Anaemia in Pregnancy: A Review. International Research in Medical and Health Sciences. 2023 Jun 10;6(2):10-13.
43. Obeagu EI, Mohamod AH. An update on Iron deficiency anaemia among children with congenital heart disease. Int. J. Curr. Res. Chem. Pharm. Sci. 2023;10(4):45-48.
44. Edward U, Osuorji VC, Nnodim J, Obeagu EI. Evaluationof Trace Elements in Sickle Cell Anaemia Patients Attending Imo State Specialist Hospital, Owerri. Madonna University journal of Medicine and Health Sciences. 2022;2(1):218-234.
45. Nwakulite A, Obeagu EI, Eze R, Ugochi VE, Vincent CC, Okafor CJ, Chukwurah EF, Unaeze BC, Amaechi CO, Okwuanaso CB, Chukwuani U. Estimation of Serum Glutathione Peroxidase in Streptozotocin Induced Diabetic Rat Treated with Bitter Leaf Extract. Journal of Pharmaceutical Research International. 2021;33(30B):200-206.
46. Okoroiwu IL, Obeagu EI, San Miguel HG, Bote SA, Obeagu GU. Characterisation of HLA-DR antigen in patients type 1 diabetes mellitus in patient attending a tertairy hospital in Enugu, south-east Nigeria. ACADEMIC JOURNAL. 2023.
47. Okoroiwu IL, Obeagu EI, Obeagu GU, Chikezie CC, Ezema GO. The prevalence of selected autoimmune diseases. Int. J. Adv. Multidiscip. Res. 2016;3(3):9-14.
48. Nwakuilite A, Nwanjo HU, Nwosu DC, Obeagu EI. EVALUATION OF ENZYME ANTIOXIDANTS IN STREPTOZOCIN INDUCED DIABETIC RATS TREATED WITH MORINGA OLEIFERA LEAF POWDER. European Journal of Biomedical. 2020;7(11):285-288.

49. Nwosu DC, Nwanjo HU, Opara AU, Ofor IB, Obeagu EI, Ugwu GU, Ojiegbe GC, Nnorom RM, Nwokike GI, Okpara KE, Ochei KC. EVALUATION OF C-REACTIVE PROTEIN, SELENIUM AND GLYCOSYLATED HAEMOGLOBIN LEVELS IN DIABETIC PATIENTS ATTENDING METABOLIC CLINIC IN THE FEDERAL MEDICAL CENTRE, OWERRI, IMO STATE. **World Journal of Pharmacy and Pharmaceutical Sciences, 2015; 4 (3):141-152.** https://www.academia.edu/download/38320132/NWOSU_EMMA_9.pdf.
50. Nwakuilite A, Nwanjo HU, Nwosu DC, Obeagu EI. EVALUATION OF KIDNEY INJURY MOLECULE-1, CYSTATIN C, AND SERUM ELECTROLYTES IN STREPTOZOCIN INDUCED DIABETIC RATS TREATED WITH MORINGA OLEIFERA LEAF POWDER. Education. 2002.
51. Ugwu OP, Alum EU, Okon MB, Aja PM, Obeagu EI, Onyeneke EC. Anti-nutritional and gas chromatography-mass spectrometry (GC-MS) analysis of ethanol root extract and fractions of Sphenocentrum jollyanum. RPS Pharmacy and Pharmacology Reports. 2023;2(2): rqad007.
52. Obeagu EI, Scott GY, Amekpor F, Ugwu OP, Alum EU. Covid-19 Infection and Diabetes: A Current Issue. International Journal of Innovative and Applied Research. 2023;11(1):25-30.
53. Ugwu OP, Alum EU, Obeagu EI, Okon MB, Aja PM, Samson AO, Amusa MO, Adepoju AO. Effect of Ethanol leaf extract of Chromolaena odorata on lipid profile of streptozotocin induced diabetic wistar albino rats. IAA Journal of Biological Sciences. 2023;10(1):109-117.
54. Ifeanyi OE. Gestational Diabetes: Haematological Perspective. **South Asian Research Journal of Applied Medical Sciences, 1 (2):41-42. DOI: 10.36346/SARJAMS.2019.v01i02.003** https://sarpublication.com/media/articles/SARJAMS_12_41-42.pdf.
55. Umar MI, Aliyu F, Abdullahi MI, Aliyu MN, Isyaku I, Aisha BB, Sadiq RU, Shariff MI, Obeagu EI. Assessment Of Factors Precipitating Sickle Cell Crises Among Under 5-Years Children Attending Sickle Cell Clinic Of Murtala Muhammad Specialist Hospital, Kano. blood.;11:16.
56. Obeagu EI. Vaso-occlusion and adhesion molecules in sickle cells disease. Int J Curr Res Med Sci. 2018;4(11):33-35.
57. Ifeanyi OE, Stella EI, Favour AA. Antioxidants In The Management of Sickle Cell Anaemia. Int J Hematol Blood Disord (Internet) 2018 (cited 2021 Mar 4); 3. Available from: https://symbiosisonlinepublishing. com/hematology/hema tology25. php. 2018 Sep.
58. Buhari HA, Ahmad AS, Obeagu EI. Current Advances in the Diagnosis and Treatment of Sickle Cell Anaemia. APPLIED SCIENCES (NIJBAS). 2023;4(1).
59. Nnodim J, Uche U, Ifeoma U, Chidozie N, Ifeanyi O, Oluchi AA. Hepcidin and erythropoietin level in sickle cell disease. British Journal of Medicine and Medical Research. 2015;8(3):261-5.

60. Obeagu EI. BURDEN OF CHRONIC OSTEOMYLITIS: REVIEW OF ASSOCIATIED FACTORS. Madonna University journal of Medicine and Health Sciences. 2023;3(1):1-6.
61. Aloh GS, Obeagu EI, Okoroiwu IL, Odo CE, Chibunna OM, Kanu SN, Elemchukwu Q, Okpara KE, Ugwu GU. Antioxidant-Mediated Heinz Bodies Levels of Sickle Erythrocytes under Drug-Induced Oxidative Stress. European Journal of Biomedical and Pharmaceutical sciences. 2015;2(1):502-507.
62. Obeagu EI, Malot S, Obeagu GU, Ugwu OP. HIV resistance in patients with Sickle Cell Anaemia. Newport International Journal of Scientific and Experimental Sciences (NIJSES). 2023;3(2):56-9.
63. Obeagu EI, Bot YS, Opoku D, Obeagu GU, Hassan AO. Sickle Cell Anaemia: Current Burden in Africa. International Journal of Innovative and Applied Research. 2023;11(2):12-14.
64. Obeagu EI, Obeagu GU. Sickle Cell Anaemia in Pregnancy: A Review. International Research in Medical and Health Sciences. 2023 Jun 10; 6 (2): 10-13.
65. Obeagu EI, Ogbuabor BN, Ikechukwu OA, Chude CN. Haematological parameters among sickle cell anemia patients' state and haemoglobin genotype AA individuals at Michael Okpara University of Agriculture, Umudike, Abia State, Nigeria. International Journal of Current Microbiology and Applied Sciences. 2014;3(3):1000-1005.
66. Ifeanyi OE, Nwakaego OB, Angela IO, Nwakaego CC. Haematological parameters among sickle cell anaemia... Emmanuel Ifeanyi1, et al. pdf• Obeagu. Int. J. Curr. Microbiol. App. Sci. 2014;3(3):1000-1005.
67. Obeagu EI, Abdirahman BF, Bunu UO, Obeagu GU. Obsterics characteristics that effect the newborn outcomes. Int. J. Adv. Res. Biol. Sci. 2023;10(3):134-143.
68. Obeagu EI, Opoku D, Obeagu GU. Burden of nutritional anaemia in Africa: A Review. Int. J. Adv. Res. Biol. Sci. 2023;10(2):160-163.
69. Ifeanyi E. Erythropoietin (Epo) Level in Sickle Cell Anaemia (HbSS) With Falciparum Malaria Infection in University Health Services, Michael Okpara University of Agriculture, Umudike, Abia State, Nigeria. PARIPEX - INDIAN JOURNAL OF RESEARCH, 2015; 4(6): 258-259
70. Ifeanyi OE, Nwakaego OB, Angela IO, Nwakaego CC. Haematological parameters among sickle cell anaemia patients in steady state and haemoglobin genotype AA individuals at Michael Okpara, University of Agriculture, Umudike, Abia State, Nigeria. Int. J. Curr. Microbiol. App. Sci. 2014;3(3):1000-1005.
71. Ifeanyi OE, Stanley MC, Nwakaego OB. Comparative analysis of some haematological parameters in sickle cell patients in steady and crisis state at michael okpara University of agriculture, Umudike, Abia state, Nigeria. Int. J. Curr. Microbiol. App. Sci. 2014;3(3):1046-1050.
72. Ifeanyi EO, Uzoma GO. Malaria and The Sickle Cell Trait: Conferring Selective Protective Advantage to Malaria. J Clin Med Res. 2020; 2:1-4.
73. Ogbu IS, Odeh EJ, Ifeanyichukwu OE, Ogbu C, Ude UA, Obeagu EI. Prevalence of prediabetes among first degree relatives of type 2 diabetes individuals in Abakaliki, Ebonyi

State Nigeria. Academic Journal of Health Sciences: Medicina Balear. 2023;38(2):85-88. https://dialnet.unirioja.es/servlet/articulo?codigo=8845439.

74. Ifeanyi OE. An update on Diabetes Mellitus. Int. J. Curr. Res. Med. Sci. 2018;4(6):71-81.DOI: 10.22192/ijcrms.2018.04.06.012 links/5b3b97a04585150d23f63e76/An-update-on-Diabetes-Mellitus.pdf.
75. Obeagu EI, Obeagu GU. Improving Outcomes: Integrated Strategies for Diabetes and Sickle Cell Anemia. Int. J. Curr. Res. Chem. Pharm. Sci. 2024;11(2):20-9.
76. Obeagu EI, Obeagu GU. Dual Management: Diabetes and Sickle Cell Anemia in Patient Care. Elite Journal of Medicine. 2024;2(1):47-56.
77. Chakrabarty S, Mishra MP. Health Literacy Initiatives in the Donation Landscape: Educating for Impact. InThe Role of Health Literacy in Major Healthcare Crises 2024: 260-284. IGI Global.
78. Pandya M, Banait S, Daigavane S. Insights into Visual Rehabilitation: Pan-Retinal Photocoagulation for Proliferative Diabetic Retinopathy. Cureus. 2024;16(2).
79. Pour AH, Rokhafrooz D, Ghahfarokhi SM, Mirmoghtadaie Z. Effect of Family-Centered Empowerment Model Using Mobile Learning on the Quality of Life in Children with Thalassemia: A Quasi-Experimental Study. Jundishapur Journal of Chronic Disease Care. 2024;13(1).